CHGCY
Chugai Pharmaceutical Co., Ltd.
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Strong sell
-78/100
Last price
19.28
▼ 0.03 (0.16%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
19.31
Day high
19.32
Day low
19.14
Volume
62.41K
Market cap
$63.45B
P/E (TTM)
20.73
52W range
19.00 – 34.84
Trailing performance
Returnvs SPY
1W
+0.05%
-1.9%
1M
-10.70%
-11.9%
3M
-14.50%
-19.0%
6M
-29.89%
-48.1%
YTD
-26.61%
-40.9%
1Y
-19.13%
-35.5%
3Y
+25.28%
-57.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CHGCY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$63.45B
Enterprise value$-899.13B
Revenue (TTM)$1.34T
Gross profit$958.00B
EBITDA$678.05B
Net income$471.37B
EPS (TTM)$0.93
Free cash flow$332.30B
Total cash$962.57B
Total debt$0
Book value / share$3.90
Shares outstanding3.29B
Float1.28B
Short % of float—
Dividend yield3.46%
Beta (5Y)0.56
Valuation & profitability ratios
Trailing P/E20.73
Forward P/E—
PEG ratio1.55
Price / sales—
Price / book4.94
EV / revenue-0.67
EV / EBITDA-1.33
Gross margin71.34%
Operating margin47.09%
Profit margin35.10%
Return on equity23.49%
Return on assets17.05%
Debt / equity—
Current ratio4.35
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.26T | $1.17T | $1.11T | $1.26T | +7.5% |
| Operating revenue | $1.26T | $1.17T | $1.11T | $1.26T | +7.5% |
| Cost of revenue | $363.69B | $339.41B | $413.31B | $476.25B | +7.2% |
| Gross profit | $894.25B | $831.20B | $698.06B | $783.48B | +7.6% |
| Research & development | $187.60B | $181.44B | $174.87B | $149.63B | +3.4% |
| Selling, general & admin | $116.46B | $110.10B | $112.58B | $100.48B | +5.8% |
| Total operating expense | $295.42B | $289.20B | $258.89B | $250.17B | +2.2% |
| Operating income | $598.83B | $542.00B | $439.17B | $533.31B | +10.5% |
| Net interest income | -$1.03B | $1.03B | $4.65B | -$9.00M | -199.4% |
| Pre-tax income | $597.81B | $543.03B | $443.82B | $531.17B | +10.1% |
| Tax provision | $163.79B | $155.72B | $118.35B | $156.74B | +5.2% |
| Net income to common | $434.01B | $387.32B | $325.47B | $374.43B | +12.1% |
| Basic EPS | 131.87 | 117.70 | 98.92 | 113.82 | +12.0% |
| Diluted EPS | 131.86 | 117.68 | 98.90 | 113.79 | +12.0% |
| EBIT | $598.01B | $542.00B | $443.85B | $531.23B | +10.3% |
| EBITDA | $598.01B | $542.00B | $443.85B | $531.23B | +10.3% |
| Basic shares | 3.29B | 3.29B | 3.29B | 3.29B | +0.0% |
| Diluted shares | 3.29B | 3.29B | 3.29B | 3.29B | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $426.60B | $540.20B | $458.67B | $222.17B | -21.0% |
| Cash & short-term investments | $979.70B | $996.35B | $738.98B | $503.11B | -1.7% |
| Accounts receivable | $442.88B | $334.26B | $318.89B | $512.54B | +32.5% |
| Inventory | $276.85B | $240.07B | $273.48B | $292.21B | +15.3% |
| Total current assets | $1.74T | $1.61T | $1.37T | $1.34T | +8.4% |
| Property, plant & equipment | $479.48B | $441.55B | $420.70B | $386.65B | +8.6% |
| Goodwill & intangibles | $54.54B | $17.87B | $19.86B | $25.14B | +205.2% |
| Total assets | $2.47T | $2.21T | $1.93T | $1.87T | +11.8% |
| Total current liabilities | $411.08B | $290.36B | $288.22B | $423.73B | +41.6% |
| Total liabilities | $442.86B | $306.87B | $306.97B | $445.37B | +44.3% |
| Shareholder equity | $2.03T | $1.90T | $1.63T | $1.42T | +6.5% |
| Working capital | $1.33T | $1.32T | $1.08T | $912.81B | +1.1% |
| Net tangible assets | $1.97T | $1.88T | $1.61T | $1.40T | +4.6% |
| Shares issued | 1.68B | 1.68B | 1.68B | 1.64B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $650.93B | $589.55B | $462.72B | $575.35B | +10.4% |
| Change in working capital | -$79.65B | -$28.84B | $130.63B | -$183.31B | -176.2% |
| Operating cash flow | $386.28B | $447.60B | $409.93B | $243.58B | -13.7% |
| Capital expenditure | -$111.61B | -$54.90B | -$74.26B | -$71.24B | -103.3% |
| Investing cash flow | -$201.27B | -$227.37B | -$37.29B | -$145.47B | +11.5% |
| Share buybacks | -$6.00M | -$10.00M | -$5.00M | -$5.00M | +40.0% |
| Dividends paid | -$299.42B | -$133.25B | -$131.59B | -$138.22B | -124.7% |
| Financing cash flow | -$307.89B | -$141.01B | -$139.33B | -$145.64B | -118.3% |
| Free cash flow | $274.67B | $392.70B | $335.67B | $172.34B | -30.1% |
| End cash position | $426.60B | $540.20B | $458.67B | $222.17B | -21.0% |
| Line item | 2026-03-31 | 2025-03-31 | YoY |
|---|---|---|---|
| Basic EPS | 35.07 | 29.55 | +18.7% |
| Diluted EPS | 35.07 | 29.54 | +18.7% |
| Basic shares | 3.29B | 3.29B | +0.0% |
| Diluted shares | 3.29B | 3.29B | -0.0% |
| Line item | 2026-06-30 | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $390.44B | $426.60B | $497.09B | -8.5% |
| Cash & short-term investments | $962.57B | $979.70B | $1.03T | -1.7% |
| Accounts receivable | $381.85B | $442.88B | $316.75B | -13.8% |
| Inventory | $317.58B | $276.85B | $235.53B | +14.7% |
| Total current assets | $1.70T | $1.74T | $1.62T | -2.1% |
| Property, plant & equipment | $503.48B | $479.48B | $471.35B | +5.0% |
| Goodwill & intangibles | $59.28B | $54.54B | $33.29B | +8.7% |
| Total assets | $2.45T | $2.47T | $2.28T | -0.8% |
| Total current liabilities | $392.19B | $411.08B | $268.28B | -4.6% |
| Total liabilities | $422.25B | $442.86B | $293.22B | -4.7% |
| Shareholder equity | $2.03T | $2.03T | $1.99T | +0.1% |
| Working capital | $1.31T | $1.33T | $1.35T | -1.3% |
| Net tangible assets | $1.97T | $1.97T | $1.95T | -0.1% |
| Shares issued | 1.68B | 1.68B | 1.68B | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $348.29B | +4.5% |
| Next quarter | — | — | $367.30B | +6.1% |
| Current year | — | — | $1.38T | +10.9% |
| Next year | — | — | $1.52T | +10.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions0.06%
Institutions holding25
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
19.94
-3.33% from price
SMA 20
20.49
-5.91% from price
SMA 50
21.22
-9.14% from price
SMA 100
22.30
-13.54% from price
SMA 200
25.09
-23.15% from price
EMA 12
19.94
-3.31% from price
EMA 26
20.55
-6.16% from price
EMA 50
21.20
-9.04% from price
RSI (14)
33.0
Neutral
MACD (12,26,9)
-0.61
Hist -0.16
ATR (14)
1.15
5.97% of price
Realised vol 30D
27.2%
Annualised
Bollinger upper
22.22
20, 2σ
Bollinger lower
18.76
20, 2σ
50 / 200 cross
Death
21.22 vs 25.09
Trend bias
Below 200
-23.15%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.77
Less volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
27.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-43.2%
Peak to trough
Max drawdown 5Y
-43.2%
Peak to trough
ATR 14
1.15
5.97% of price
Beta (reported)
0.56
5Y monthly, from filing
Dividends & splits
Forward rate$0.67 / yr
Forward yield3.46%
5-year avg yield1.90%
Payout ratio48.40%
Ex-dividend dateJun 30, 2026
Next pay dateSep 14, 2021
Last split12:1
Split dateJul 6, 2020
Headlines
Will Regaining Emugrobart Rights and Refocusing on SMA Change Chugai Pharmaceutical's (TSE:4519) Narrative
Simply Wall St. · 2d ago
Oil Bills, Bond Yields, Tech Jitters Damp Asian Stock Markets
MT Newswires · 8d ago
Roche Halts Development of Obesity Drug Candidate
The Wall Street Journal · 9d ago
Chugai Pharmaceutical And 2 Japanese AI Healthcare Stocks To Own
Simply Wall St. · 11d ago
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
Business Wire · 28d ago
Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight
PR Newswire · 35d ago
3 Japanese AI Healthcare Stocks Investors May Want To Watch
Simply Wall St. · 41d ago
RG-6299 Sales Forecast, and Market Size Analysis - 2034 Released — Examines Mechanism, Dosing, Pricing, Patents, and Emerging Competitors
GlobeNewswire · 51d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.